Kött, J.; Merkle, M.; Bergmann, L.; Zimmermann, N.; Zell, T.; Heidrich, I.; Geidel, G.; Pantel, K.; Schneider, S.W.; Gebhardt, C.;
et al. Comprehensive Assessment of Prognostic Factors for Immune-Related Adverse Events in Immune Checkpoint Inhibitor-Treated Melanoma. Cancers 2025, 17, 2806.
https://doi.org/10.3390/cancers17172806
AMA Style
Kött J, Merkle M, Bergmann L, Zimmermann N, Zell T, Heidrich I, Geidel G, Pantel K, Schneider SW, Gebhardt C,
et al. Comprehensive Assessment of Prognostic Factors for Immune-Related Adverse Events in Immune Checkpoint Inhibitor-Treated Melanoma. Cancers. 2025; 17(17):2806.
https://doi.org/10.3390/cancers17172806
Chicago/Turabian Style
Kött, Julian, Myriam Merkle, Lina Bergmann, Noah Zimmermann, Tim Zell, Isabel Heidrich, Glenn Geidel, Klaus Pantel, Stefan W. Schneider, Christoffer Gebhardt,
and et al. 2025. "Comprehensive Assessment of Prognostic Factors for Immune-Related Adverse Events in Immune Checkpoint Inhibitor-Treated Melanoma" Cancers 17, no. 17: 2806.
https://doi.org/10.3390/cancers17172806
APA Style
Kött, J., Merkle, M., Bergmann, L., Zimmermann, N., Zell, T., Heidrich, I., Geidel, G., Pantel, K., Schneider, S. W., Gebhardt, C., & Smit, D. J.
(2025). Comprehensive Assessment of Prognostic Factors for Immune-Related Adverse Events in Immune Checkpoint Inhibitor-Treated Melanoma. Cancers, 17(17), 2806.
https://doi.org/10.3390/cancers17172806